+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tobi/Tobi Podhaler

  • PDF Icon

    Report

  • 17 Pages
  • September 2018
  • Region: Global
  • Pharma Intelligence
  • ID: 4775278
Drug Overview
Tobi and the next-generation Tobi Podhaler are the gold-standard inhaled antibiotic treatments for cystic fibrosis patients.

Long-term treatment with Tobi and Tobi Podhaler treats chronic Pseudomonas aeruginosa infections that are common in cystic fibrosis patients and also has other respiratory benefits such as improving lung function.

Table of Contents

CONTENTS
OVERVIEW
Drug Overview
Product Profiles
Tobi/Tobi Podhaler : Cystic fibrosis
LIST OF FIGURES
Figure 1: Tobi/Tobi Podhaler for cystic fibrosis – SWOT analysis
Figure 2: The authors drug assessment summary of Tobi/Tobi Podhaler for cystic fibrosis
Figure 3: The authors drug assessment summary of Tobi/Tobi Podhaler for cystic fibrosis
Figure 4: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
Table 1: Tobi/Tobi Podhaler drug profile
Table 2: Tobi/Tobi Podhaler Phase III data in cystic fibrosis
Table 3: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25